1Massachusetts General Hospital (United States) 2Lovelace Biomedical Research Institute (United States) 3University of New Mexico School of Medicine (United States) 4VA Boston Healthcare System, U.S. Dept. of Veterans Affairs (United States)
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Photobiomodulation (PBM) with low-power near-infrared (NIR) light has shown diverse beneficial effects. Recent studies report that PBM also increases bioavailable nitric oxide (NO), which is a critical gaseous mediator for various physiological processes and could be used to treat cardiovascular and cerebrovascular diseases with suppressed endothelial NO production. We explored using NIR-II light (1000-1700 nm) for PBM. NIR-II laser treatment efficiently enhanced NO generation in endothelial cells. Since impaired NO production is also associated with neurological diseases, this novel therapy could be further explored to treat diseases such as traumatic brain injury, sleep disorders, and Alzheimer's disease.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Shinya Yokomizo, Denis E. Bragin, Dmitry Gerashchenko, Dmitriy N. Atochin, Satoshi Kashiwagi, "Near-infrared II photobiomodulation to treat cardiovascular diseases via restoring endothelial nitric oxide bioavailability," Proc. SPIE PC12826, Mechanisms of Photobiomodulation Therapy XVIII, PC1282604 (13 March 2024); https://doi.org/10.1117/12.3003398